Aliases & Classifications for Neurilemmoma

Aliases & Descriptions for Neurilemmoma:

Name: Neurilemmoma 12 42 14 69
Schwannoma 12 29 52 14
Psammomatous Schwannoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3192
MeSH 42 D009442
NCIt 47 C3269
UMLS 69 C0027809

Summaries for Neurilemmoma

MalaCards based summary : Neurilemmoma, also known as schwannoma, is related to melanotic neurilemmoma and benign schwannoma. An important gene associated with Neurilemmoma is NF2 (Neurofibromin 2), and among its related pathways/superpathways are ERK Signaling and Cytoskeletal Signaling. The drugs Anti-Bacterial Agents and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include tongue, thyroid and bone, and related phenotypes are Decreased viability and behavior/neurological

Wikipedia : 71 A schwannoma is a benign nerve sheath tumor composed of Schwann cells, which normally produce the... more...

Related Diseases for Neurilemmoma

Diseases related to Neurilemmoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
id Related Disease Score Top Affiliating Genes
1 melanotic neurilemmoma 33.1 GFAP NF2 SMARCB1
2 benign schwannoma 31.7 S100B VIM
3 thoracic outlet syndrome 29.7 NF1 NF2 SMARCB1
4 ganglioneuroma 29.4 KIT PDGFRA
5 mediastinal neurilemmoma 11.8
6 sympathetic neurilemmoma 11.8
7 neurilemmoma of the fifth cranial nerve 11.7
8 neurilemmoma of the pleura 11.7
9 benign dermal neurilemmoma 11.7
10 macrocystic neurilemmoma 11.7
11 benign mediastinal psammomatous neurilemmoma 11.7
12 benign mediastinal neurilemmoma 11.7
13 schwannomatosis 11.5
14 cellular schwannoma 11.2
15 acoustic neuroma 11.0
16 plexiform schwannoma 11.0
17 malignant peripheral nerve sheath tumor 10.9
18 schwannoma of jugular foramen 10.7
19 watson syndrome 10.3 NF1 NF2
20 distal trisomy 10q 10.3 NF2 SMARCB1
21 cervical adenoid cystic carcinoma 10.3 GFAP NF1
22 leiomyomatosis 10.3 GFAP KIT
23 myelinoclastic diffuse sclerosis 10.3 GFAP S100B
24 bronchitis 10.3 GFAP NF2
25 idiopathic cd4-positive t-lymphocytopenia 10.3 SMARCB1 SOX10
26 thrombophlebitis 10.3 GFAP SMARCB1
27 pediatric cns embryonal cell carcinoma 10.3 GFAP NF2
28 epilepsy, familial focal, with variable foci 10.3 EZR NF1 NF2
29 pathologic nystagmus 10.2 NF1 NF2 S100B
30 porokeratosis 10.2 GFAP NF2 S100B
31 pineal dysgerminoma 10.2 GFAP NF1 NF2
32 bronchial mucus gland adenoma 10.2 GFAP S100B
33 hypothalamic neoplasm 10.2 GFAP NES
34 angiofollicular lymph hyperplasia 10.2 GFAP NES
35 lupus - neurological sequelae 10.2 S100B VIM
36 cervicitis 10.2
37 invasive mole 10.2 KIT PDGFRA S100B
38 connective tissue cancer 10.2 GFAP NF2 S100B
39 fibrosarcoma 10.2 KIT PDGFRA SMARCB1
40 external ear disease 10.2 GFAP NF2
41 mongolian spot 10.2 NF1 S100B SOX10
42 t-cell large granular lymphocyte leukemia 10.2 NF1 NF2 PRKAR1A
43 endocrine organ benign neoplasm 10.2 KIT NF1 NF2 SMARCB1
44 surfactant metabolism dysfunction, pulmonary, 5 10.2 NF1 NF2 PRKAR1A SMARCB1
45 intracranial sinus thrombosis 10.2 KIT VIM
46 granulomatous myositis 10.2 NES NF1 NF2
47 granular cell leiomyosarcoma 10.2 EZR GFAP S100B
48 glucosidase acid-1,4-alpha deficiency 10.2 DES GFAP
49 carbon monoxide-induced parkinsonism 10.2 DES KIT
50 central nervous system sarcoma 10.2 GFAP KIT NF1 SMARCB1

Graphical network of the top 20 diseases related to Neurilemmoma:



Diseases related to Neurilemmoma

Symptoms & Phenotypes for Neurilemmoma

GenomeRNAi Phenotypes related to Neurilemmoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.33 PDGFRA
2 Decreased viability GR00221-A-1 10.33 SMARCB1 PDGFRA PRKAR1A KIT NF1
3 Decreased viability GR00221-A-2 10.33 PRKAR1A SMARCB1 NF1
4 Decreased viability GR00221-A-3 10.33 PRKAR1A SMARCB1 NF2 PDGFRA
5 Decreased viability GR00221-A-4 10.33 PRKAR1A PDGFRA NF1
6 Decreased viability GR00301-A 10.33 KIT
7 Decreased viability GR00381-A-1 10.33 SMARCB1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.9 S100B SMARCB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.9 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.9 SOX10
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.9 VIM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.9 SMARCB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.9 SOX10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.9 SMARCB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.9 VIM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.9 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.9 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.9 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.9 VIM SMARCB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.9 SOX10 VIM
21 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.9 VIM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.9 VIM
23 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.9 SMARCB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.9 VIM
25 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.9 KIT VIM
26 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.9 SOX10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.9 KIT
28 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.9 SOX10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.9 VIM S100B
30 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.9 SOX10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.9 SOX10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.9 SOX10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.9 SMARCB1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.9 SOX10 KIT VIM S100B SMARCB1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.9 KIT
36 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.9 KIT
37 Increased proliferation GR00094-A 8.96 SMARCB1 NF2

MGI Mouse Phenotypes related to Neurilemmoma:

44 (show all 22)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 PDGFRA PRKAR1A S100B SMARCB1 SOX10 TYR
2 cellular MP:0005384 10.37 DES GFAP KIT MBP NF1 NGFR
3 homeostasis/metabolism MP:0005376 10.37 DES GFAP KIT MBP NF1 NF2
4 growth/size/body region MP:0005378 10.34 EZR GFAP KIT MBP NF1 NF2
5 cardiovascular system MP:0005385 10.3 DES GFAP KIT NF1 NGFR PDGFRA
6 mortality/aging MP:0010768 10.3 DES EZR GFAP KIT MBP NF1
7 immune system MP:0005387 10.29 EZR GFAP KIT MBP TYR VIM
8 digestive/alimentary MP:0005381 10.23 EZR GFAP KIT NF1 NGFR PDGFRA
9 embryo MP:0005380 10.22 TYR VIM KIT NF1 NF2 PDGFRA
10 hematopoietic system MP:0005397 10.19 EZR KIT MBP NF1 NGFR PDGFRA
11 craniofacial MP:0005382 10.13 KIT NF1 NF2 NGFR PDGFRA PRKAR1A
12 nervous system MP:0003631 10.11 GFAP KIT MBP NF1 NF2 NGFR
13 integument MP:0010771 10.1 KIT NF1 NF2 NGFR PDGFRA S100B
14 muscle MP:0005369 10.09 DES GFAP KIT NF1 NGFR PDGFRA
15 hearing/vestibular/ear MP:0005377 10.02 KIT MBP NF1 NF2 NGFR TYR
16 normal MP:0002873 10.02 GFAP KIT MBP NF1 NGFR PDGFRA
17 neoplasm MP:0002006 10.01 KIT NF1 NF2 PDGFRA PRKAR1A SMARCB1
18 limbs/digits/tail MP:0005371 9.95 KIT NF1 NGFR PDGFRA SOX10 TYR
19 reproductive system MP:0005389 9.76 KIT MBP NF2 PDGFRA PRKAR1A SMARCB1
20 pigmentation MP:0001186 9.73 KIT NF1 PDGFRA PRKAR1A SOX10 TYR
21 respiratory system MP:0005388 9.56 KIT NF1 NF2 NGFR PDGFRA PRKAR1A
22 vision/eye MP:0005391 9.32 SMARCB1 TYR VIM GFAP KIT MBP

Drugs & Therapeutics for Neurilemmoma

Drugs for Neurilemmoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
2 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Early Phase 1
3 Gentamicins Phase 4
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
6
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
7
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
8
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
9
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
10
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
11 Alkylating Agents Phase 3,Phase 2,Phase 1
12 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
13 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
14 Isophosphamide mustard Phase 3,Phase 2
15 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
16 Protein Kinase Inhibitors Phase 2, Phase 3,Early Phase 1
17 Antiemetics Phase 3
18 Anti-Inflammatory Agents Phase 3,Phase 2
19 Antineoplastic Agents, Hormonal Phase 3
20 Autonomic Agents Phase 3
21 Gastrointestinal Agents Phase 3
22 glucocorticoids Phase 3
23 Hormone Antagonists Phase 3
24 Hormones Phase 3
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
26 Methylprednisolone acetate Phase 3
27 Methylprednisolone Hemisuccinate Phase 3
28 Neuroprotective Agents Phase 3
29 Peripheral Nervous System Agents Phase 3,Phase 2
30 Prednisolone acetate Phase 3
31 Prednisolone hemisuccinate Phase 3
32 Prednisolone phosphate Phase 3
33 Protective Agents Phase 3,Phase 2
34 Imatinib Mesylate Phase 2, Phase 3 123596
35
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
36
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
37
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
38
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
39
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
40
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
41
Etoposide Approved Phase 2 33419-42-0 36462
42
Lenograstim Approved Phase 2 135968-09-1
43
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
44
Pembrolizumab Approved Phase 2 1374853-91-4
45
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492
46
nivolumab Approved Phase 2 946414-94-4
47
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
48
Xylometazoline Approved Phase 1, Phase 2 526-36-3 5709
49
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
50
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316

Interventional clinical trials:

(show top 50) (show all 88)
id Name Status NCT ID Phase
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4
2 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4
3 Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors Enrolling by invitation NCT02884154 Phase 4
4 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
5 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
6 Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery Completed NCT00438087 Phase 3
7 Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. Recruiting NCT02249572 Phase 2, Phase 3
8 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
9 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
10 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3
11 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
12 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2
13 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2
14 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2
15 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2
16 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2
17 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2
18 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2
19 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2
20 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
21 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
22 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Recruiting NCT01345136 Phase 2
23 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Recruiting NCT02129647 Phase 2
24 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
25 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2
26 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Recruiting NCT02934256 Phase 2
27 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2
28 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Recruiting NCT02831257 Phase 2
29 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2
30 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2
31 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
32 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2
33 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2
34 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2
35 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
36 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Active, not recruiting NCT02008877 Phase 1, Phase 2
37 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Active, not recruiting NCT01661283 Phase 2
38 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Active, not recruiting NCT01653028 Phase 2
39 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
40 Trial of Dasatinib in Advanced Sarcomas Active, not recruiting NCT00464620 Phase 2
41 Study of Aspirin in Patients With Vestibular Schwannoma Not yet recruiting NCT03079999 Phase 2
42 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Not yet recruiting NCT02986919 Phase 2
43 PTC299 for Treatment of Neurofibromatosis Type 2 Suspended NCT00911248 Phase 2
44 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2
45 Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma Terminated NCT02988726 Phase 2
46 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2
47 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1
48 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1
49 An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Completed NCT00030043 Phase 1
50 Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery Recruiting NCT02700230 Phase 1

Search NIH Clinical Center for Neurilemmoma

Cochrane evidence based reviews: neurilemmoma

Genetic Tests for Neurilemmoma

Genetic tests related to Neurilemmoma:

id Genetic test Affiliating Genes
1 Schwannoma 29

Anatomical Context for Neurilemmoma

MalaCards organs/tissues related to Neurilemmoma:

39
Tongue, Thyroid, Bone, Breast, Kidney, Lymph Node, Tonsil

Publications for Neurilemmoma

Articles related to Neurilemmoma:

(show top 50) (show all 450)
id Title Authors Year
1
Intraventricular Neurilemmoma (Schwannoma): Shall GFAP Immunostaining Be Regarded as a Histogenetical Tag or as a Mere Histomimetical Trait? ( 27446622 )
2016
2
Schwannoma (Neurilemmoma) on the Base of the Tongue: A Rare Clinical Case. ( 27018477 )
2016
3
Cervical vagus nerve neurilemmoma mimicking parathyroid adenoma. ( 27562903 )
2016
4
Neurilemmoma in the floor of the mouth: a case report. ( 26904498 )
2016
5
Recurrent Ancient Intraosseous Neurilemmoma of Maxilla: A Rare Case Report. ( 27499782 )
2016
6
Neurilemmoma of the Vagus Nerve in the Poststyloid Parapharyngeal Space. ( 26894190 )
2016
7
Neurilemmoma of Retromolar Region in the Oral Cavity. ( 26221545 )
2015
8
Benign paravertebral ancient neurilemmoma in a young adult: a rare occurrence. ( 25738029 )
2015
9
Surgical outcome of spinal neurilemmoma: two case reports. ( 25654395 )
2015
10
Vaginal Neurilemmoma: Case Report with Brief Review. ( 27217689 )
2015
11
Thoracic Neurilemmoma Presenting With Spinal Nerve Involvement in Promyelocytic Leukemia. ( 25950139 )
2015
12
Neurilemmoma of Deep Peroneal Nerve Sensory Branch : Thermographic Findings with Compression Test. ( 26539275 )
2015
13
Primary Neurilemmoma of the Thyroid Gland Clinically Mimicking Malignant Thyroid Nodule. ( 26498011 )
2015
14
Intestinal neurilemmoma. ( 24157416 )
2014
15
Neurilemmoma of median nerve. ( 25983466 )
2014
16
Intraosseous neurilemmoma of the proximal ulna. ( 25460435 )
2014
17
Neurilemmoma of lateral nasal wall. ( 25179720 )
2014
18
Penile neurilemmoma: Utility of fine-needle aspiration cytology in diagnosis of a rare entity. ( 25538392 )
2014
19
Ancient neurilemmoma: A rare oral tumor. ( 24574671 )
2013
20
Laparoscopic phrenectomy for a diaphragmatic neurilemmoma. ( 24250705 )
2013
21
Human pulmonary dirofilariasis coexisting with intercostal neurilemmoma: a case report and literature review. ( 24080016 )
2013
22
Lateral cervical approach combined with posterior thoracotomy for the treatment of giant neurilemmoma of the chest involving the neck. ( 22884113 )
2013
23
Maxillary neurilemmoma-Rarest of the rare tumour: Report of 2 cases. ( 24129122 )
2013
24
Neurilemmoma Showing a Unique Growth Pattern in the Lateral Chest Wall: Both Inside and Outside the Thoracic Cavity. ( 23445787 )
2013
25
Neurilemmoma of the thyroid gland. ( 22728508 )
2012
26
Rectal schwannoma (neurilemmoma). ( 22369805 )
2012
27
Hibernoma in the thoracic back muscle accompanied by neurilemmoma. ( 25983847 )
2012
28
Multiple neurilemmomas in Birt-Hogg-DubAc syndrome: case report. ( 22326190 )
2012
29
Giant neurilemmoma of the vagus nerve: a case report and review of literature. ( 23936960 )
2012
30
Value of ultrasonography in neurilemmoma diagnosis: the role of round shape morphology. ( 22957323 )
2012
31
Intraosseous neurilemmoma of the mandible: report of a rare ancient type. ( 22013479 )
2011
32
Mesentery neurilemmoma: CT, MRI and angiographic findings. ( 22041360 )
2011
33
Lower neck neurilemmoma can masquerade as lymph node metastasis on FDG PET/CT in patient with nasopharyngeal carcinoma. ( 22064115 )
2011
34
Neurilemmoma (schwannoma) of the thyroid gland: a rare case presentation. ( 21045459 )
2010
35
Neurilemmoma presenting as a midline nasal mass in a pediatric patient. ( 20461682 )
2010
36
Dermal schwannoma (neurilemmoma): a peculiar foreign body reaction? ( 20216197 )
2010
37
Mandible schwannoma (neurilemmoma) presenting as periapical lesion. ( 19225090 )
2009
38
Neurilemmoma of the first branch of the lateral plantar nerve causing tarsal tunnel syndrome. ( 20400427 )
2009
39
Intranodal neurilemmoma presenting as parotid mass. ( 18940018 )
2009
40
Multinodular neurilemmoma of the tongue: a case report with differential immunohistochemical profile. ( 18427374 )
2008
41
Fibroadenoma with digital fibroma-like inclusions in neurilemmoma-like stromal component. ( 18186878 )
2008
42
Wagner-Meissner neurilemmoma of the right cheek. ( 18486897 )
2008
43
Two cases of neurilemmoma of the tongue. ( 18225629 )
2007
44
Retroperitoneal neurilemmoma (schwannoma). ( 17635295 )
2007
45
Neurilemmoma of the abdomen. ( 17699937 )
2007
46
Solitary neurilemmoma in postaural region. ( 17915796 )
2007
47
Extrahepatic bile duct neurilemmoma mimicking Klatskin tumor. ( 17367238 )
2007
48
Base of tongue neurilemmoma: excision by transoral laser microsurgery. ( 17712683 )
2007
49
Recurrent multinodular neurilemmoma of the female upper lip. ( 17014991 )
2007
50
Neurilemmoma of a seminal vesicle. ( 17711752 )
2007

Variations for Neurilemmoma

Copy number variations for Neurilemmoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 163102 22 24129150 24176704 Deletion or amplific ation SMARCB1 Schwannoma

Expression for Neurilemmoma

Search GEO for disease gene expression data for Neurilemmoma.

Pathways for Neurilemmoma

GO Terms for Neurilemmoma

Cellular components related to Neurilemmoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.97 DES EZR GFAP KIT NES NF1
2 ruffle GO:0001726 9.43 EZR NF2 S100B
3 plasma membrane raft GO:0044853 9.32 EZR PRKAR1A
4 intermediate filament GO:0005882 9.26 DES GFAP NES VIM
5 intermediate filament cytoskeleton GO:0045111 8.8 DES GFAP NES

Biological processes related to Neurilemmoma according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 central nervous system development GO:0007417 9.67 MBP NES S100B
2 negative regulation of protein kinase activity GO:0006469 9.54 NF1 NF2 PRKAR1A
3 phosphatidylinositol-mediated signaling GO:0048015 9.5 EZR KIT PDGFRA
4 melanocyte differentiation GO:0030318 9.48 KIT SOX10
5 adrenal gland development GO:0030325 9.46 NF1 PDGFRA
6 MAPK cascade GO:0000165 9.46 KIT MBP NF1 PDGFRA
7 intermediate filament organization GO:0045109 9.43 DES VIM
8 negative regulation of MAPK cascade GO:0043409 9.4 NF1 NF2
9 negative regulation of cell-matrix adhesion GO:0001953 9.26 NF1 NF2
10 positive regulation of phospholipase C activity GO:0010863 8.96 KIT PDGFRA
11 pigmentation GO:0043473 8.8 KIT NF1 TYR

Molecular functions related to Neurilemmoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 structural constituent of cytoskeleton GO:0005200 9.5 DES GFAP VIM
2 protein binding GO:0005515 9.5 DES EZR GFAP KIT MBP NF1
3 protein kinase A catalytic subunit binding GO:0034236 9.26 EZR PRKAR1A
4 S100 protein binding GO:0044548 9.16 EZR S100B
5 cytoskeletal protein binding GO:0008092 9.13 DES EZR NF2

Sources for Neurilemmoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....